Canine Cancer Awareness header image 3

Mast Cell Tumor

The following information is simply informational. Its intent is not to replace the advice of a veterinarian nor to assist you in making a diagnosis of your pet. Please consult with your own veterinary physician for confirmation of any diagnosis. Your pet’s life may depend on it.

OVERVIEW

These tumors (also called mastocytomas, mast cell sarcomas) are the most frequently recognized malignant or potentially malignant neoplasms of dogs. In addition, leukemic and visceral forms can occur. A viral etiology has been speculated but remains controversial. These tumors may occur in dogs of any age (average 8-10 yr). They may occur anywhere on the body surface as well as in internal organs, but the limbs (especially the posterior upper thigh), ventral abdomen, and thorax are the most common sites; ~10% are multicentric. Many breeds appear to be predisposed, especially Boxers and Pugs (in which tumors are often multiple), Rhodesian Ridgebacks, and Boston Terriers. The tumors vary markedly in size, and clinical appearance alone cannot establish a diagnosis.

CLINICAL SIGNS

Most commonly, they appear as raised, nodular masses that on palpation may be soft to solid. Although they often seem encapsulated, mast cell tumors in dogs are seldom discrete. Rather, they consist of a highly cellular center surrounded peripherally by a “halo” of smaller numbers of mast cells that palpate as normal skin. Dogs can also develop clinical signs associated with the release of vasoactive products from the malignant mast cells. Most common is gastroduodenal ulceration that may be present in up to 25% of cases.

peanut back1.bmp

This is Peanut, a Boston Terrier presenting with what his vets have called, “the worse case” of mast cell tumors they have ever seen.

Img284.pngImg285.png

This is Cucumber, a beagle mix, with Mast Cell in it’s advanced stages. Hers began as a small lump on the left side of her muzzle. As you can see in the photos above, the cancer has caused deformity of her face, listing her nose to the right and pushing her left eye from proper seating in it’s socket. The open area by her mouth was caused by scratching most likely due to the discomfort it caused her.

DIAGNOSIS

The behavior of mast cell tumors is variable in that some are rapidly fatal and others are benign. One in eleven cases will appear as multiple nodules involving all the skin. I like to refer to mast cell tumors as cancer and “tricksters” because they can’t be trusted to behave according to their classification. Most pathologists will report them as Grade II, which means they don’t know how they’ll behave. The Grade III cases are almost always fatal. Some will appear rapidly on the face feet or axilla and resemble insect bites.

One can distinguish mast cell tumors from benign fatty tumors with cytology, the examination of cells from a fine-needle aspirate. It is excellent practice to perform cytology before surgery. I like to use New Methylene Blue stain on all my cytology specimens. The dark blue storage granules of mast cells are easy to see under microscopic examination of the stained aspirate. Early diagnosis and aggressive treatment are most effective against this common cancer.

Cytologic evaluation of Wright’s-stained, fine-needle aspirates or impression smears can be used to establish the diagnosis of mast cell tumors in dogs. However, cytology is not a substitute for histopathology—only the latter has been correlated with prognosis. Two systems of histopathologic grading have been defined, and to avoid confusion, it is essential to know which of the two systems is being used.

Although there is believed to be a benign variant of canine mast cell tumor, there is no clinical or microscopical means of identifying it. In addition, small mast cell tumors may remain quiescent for long periods before becoming aggressive. Thus, all should be treated as at least potential malignancies.

Treatment depends on the clinical stage of the disease. For Stage I tumors (a solitary tumor confined to the dermis without nodal involvement), the preferred treatment is complete excision with a wide margin; at least 3 cm of healthy tissue surrounding all palpable borders should be removed in an attempt to excise both the nodule and its surrounding “halo” of neoplastic cells. If histologic evaluation suggests that the tumor extends beyond the surgical margins, reexcision should be attempted. Alternatively, because mast cells are sensitive to radiation, radiation therapy may be curative if the remaining tumor is small or can only be seen microscopically. Combined radiation and hyperthermia may be more effective than radiation alone.At present, there is no agreed upon mode of therapy for Stage II-IV mast cell tumors. For Stage II tumors (a solitary tumor with regional lymph node involvement), options include excision of the mass and the affected regional node (if feasible), prednisolone, and radiotherapy, used either singly or in combination. Treatment of Stage III (multiple dermal tumors with or without lymph node involvement) or Stage IV (any tumor with distant metastasis or recurrence with metastasis) tumors is generally palliative. One recommended therapy is prednisolone (2 mg/kg body wt, PO, for the first 5 days, followed by a maintenance dose of 0.5 mg/kg, daily) or intralesional injections of triamcinolone (1 mg/cm diameter of tumor, every 2 wk).Treatment with H-receptor antagonists for the peripheral and gastric effects of histamine, respectively may be indicated for animals with systemic disease or clinical signs referable to histamine release. Chemotherapy with vinca alkaloids (vincristine, vinblastine), L-asparaginase, and cyclophosphamide has also been used with some effectiveness.Since intraoperative radiation therapy is the most aggressive approach being used on sarcomas in the U.S.A. today, we treat dirty tumor beds and recurrent mast cell cancer in this fashion. Our data suggests that tumor bed implants with steroids and delivering 1,000 centiGray of radiation during surgery into the tumor bed increases long term remissions and survival in animals with sarcomas of any histologic type and especially mast cell.We also deliver intratumor injections on a weekly basis and evaluate the reduction in size of non operated mast cell tumors. We also use cryotherapy to freeze small mast cell tumors in patients who have multiple small nodule disease.These techniques are attractive to clients who have old pets for which they decline anesthesia and surgery.

The Animal Cancer Institute sitesA clinical trial is now open for selected mast cell tumor patients. The objective of this study is to determine the efficacy and tolerability of a novel, oral, investigational protein kinase inhibitor for the treatment of dogs with recurrent mast cell tumors.
Clinical Trial for Canine Mast Cell Tumor Patients
Trial eligibility criteria include:

  • measurable recurrent cutaneous mast cell tumor
  • no more than one regional lymph node involved
  • no visceral (liver, spleen, intestinal) metastases
  • limited past use of chemotherapy and/or radiation therapy IS acceptable

Trial Support/Funding Includes:

  • diagnostic tests (to define eligibility and for follow up)
  • oral treatment agent
  • follow up examinations

Eligible patients will have the opportunity to receive the investigational compound under closely monitored conditions while participating in the study (limitations apply). Dogs will receive the oral medication over a 6-week initial phase. Follow-up will include weekly examinations during the initial phase and then re-check examinations every 6 weeks pending response.

 

Participating Animal Cancer Institute Network trial sites:

 

Animal Cancer Institute at Friendship Hospital

202-363-7300

Beltway Oncology and Internal Medicine

301-805-5680

Atlantic Veterinary Internal Medicine

410-224-0121

Regional Veterinary Referral Associates

703-451-8900

Southpaws Veterinary Referral Center

703-451-3635

VCA – Veterinary Referral Associates

301-340-3224

For more information please contact the Animal Cancer Institute (202-363-7300) or see their website at www.animalcancerinstitiute.com.

Clinical Trial Results:

1. Prostaglandins Leukot Essent Fatty Acids. 2003 May;Effects of fatty acids on mediators of mass cells in culture. Gueck T, Seidel A, Fuhrmann H. Faculty of Veterinary Medicine, Institute of Physiological Chemistry, University of Leipzig,
An den Tierkliniken 1, D-04103, Leipzig, Germany. gueck@vetmed.uni-leipzig.de

The objective of this study was to investigate the effects of alpha-linolenic acid (18:3n-3) and linoleic acid (18:2n-6) on the fatty acid composition and the activity and release of mast cell mediators in the canine mastocytoma cell line C2. Cells were cultured in Dulbecco’s modified Eagle’s medium mixed with 50% Ham’s F12 (containing linoleic acid 0.14 micro M). The basic medium (DEH) was supplemented with 0.14 micro M alpha-linolenic acid. 14.0 micro M alpha-linolenic acid (DEH-n-3) or 14.0 micro M linoleic acid (DEH-n-6) was added. Eight days after culturing of C2 in DEH-n-3 we measured elevated levels of n-3 fatty acids up to 22:3. The tryptase activity and the stimulated PGE2 production and histamine release were reduced. In contrast, after culturing of C2 in DEH-n-6 we determined elevated levels of n-6 fatty acids up to 20:3, increased tryptase activity and stimulated histamine release. Thus 18:3n-3 has anti-inflammatory effects in cultured canine mastocytoma cells.

PMID: 12711248 [PubMed - in process]

2. Vet Dermatol. 2002 Dec;13(6):301-5.
Influence of vitamin E on mast cell mediator release.

Gueck T, Aschenbach JR, Fuhrmann H.
Institute of Physiological Chemistry, Faculty of Veterinary Medicine, University of Leipzig, An den Tierkliniken 1, 04103 Leipzig, Germany. gueck@vetmed.uni-leipzig.de
We investigated the influence of vitamin E on mediator activity and release in a canine mastocytoma cell line (C2) as a model for canine atopic dermatitis. Cells were incubated without and with vitamin E (100 microm) for 24 h. The histamine and prostaglandin D2 (PGD2) release as well as the chymase and tryptase activity were measured. To stimulate the PGD2 and histamine release, cells were incubated with the wasp venom peptide mastoparan (50 microm) for 30 or 45 min. Nonstimulated as well as mastoparan-stimulated histamine and PGD2 release was reduced significantly in vitamin E-treated cells. The activity of chymase tended to decrease, but the tryptase activity of C2 cells was not influenced by vitamin E. These results indicate that vitamin E decreased the production and release of inflammatory mediators in C2 cells, suggesting that vitamin E might have a possible beneficial effect in inflammatory diseases.

PMID: 12464062 [PubMed - indexed for MEDLINE]

LINKS FOR ADDITIONAL INFORMATION ON MAST CELL TUMORS

AKC/Flat Coated Retriever Society

DaviesWhite Vet Specialists

Kate Connick’s Courteous Canines

Leilah’s Laughs

Vet Surgery Central

Newman Veterinary

ACKNOWLEDGMENTS

Merck Veterinary Manual 8th edition.

Many thanks and acknowledgment to Dr. Alice Villalobos, Editor-in-Cheif of the American Association of Human Animal Bond Veterinarians; Animal Oncology Consultation Service Coast Pet Clinic of Hermosa Beach, Inc. for enthusiatically granting us permission to use the above information. To read more about the wonderful work Dr. Villalobos has done in the field of animal oncology click here.

PubMed,

Published for MEDLINE, National Library of Medicine

Any information on this site is published under the “fair use” act. If you are the author, researcher or contributor to any of the information contained herein and would prefer not to have your information included on the site, please contact us and it will be removed immediately.